A new parameter in multiple myeloma: CYP3A4*1B single nucleotide polymorphism

Evaluating the Impacts of CYP3A4*1B and CYP3A5*3 Variations on Pharmacokinetic Behavior and Clinical Outcomes in Multiple Myeloma Patients With Autologous Stem Cell Transplant

“…Time to relapse was determined as the time from transplant until the earliest of the following time points: progressive disease, clinical relapse, or relapse from CR (complete response) as determined by the International Myeloma Working Group (IMWG) (28). Patients without known progression were censored at the date of last follow up.…”

“…In a prospective randomized clinical trial (HOVON-24), MM patients carrying CYP3A5*3/*3 and CYP3A4*1B/*1B (290AgG; a variant in a close linkage with the CYP3A5*3 allele) had significantly poorer progression-free survival (PFS) and overall survival (OS) after high-dose melphalan and VAD therapies than non-carriers of CYP3A5*3/*3 and CYP3A4*1B/*1B, as demonstrated in univariate survival analyses (26,27). Additionally, CYP3A4*1B SNP was found to be statistically significantly associated with OS and PFS in a cohort of MM patients with ASCT and bortezomibcyclophosphamine-dexamethasone therapy (28).…”

Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis

“…Several other chromosomal translocations and mutations were further reported that can be utilized as biomarkers in MM. These genetic alterations were found to be associated with chemotherapy-induced peripheral neuropathy [ 118 ], correlating with the outcome and survival of MM patients [ 119 , 120 , 121 , 122 , 123 , 124 , 125 ] and indicating the clinical response to treatment [ 126 , 127 ].…”

Estimation of CYP3A4*1B single nucleotide polymorphism using target-assembled in-situ detection by synthetic DNA-mounted excimers

“…The split-probe model system used in this study containing 22-mer target sequence which corresponds to a region of the CYP3A4 major genome (3'-AGCGGAGAGAGGACGGGAACAG-5') and complementary 11mer probes(5'-TCGCCTCTCTC-pyrene and pyrene-CTGCCCTTGTC-3'). CYP3A4*1B (-392A>G, rs2740574) is a CYP3A4 polymorphism and it is the frequently studied proximal promoter variant which occurs in White humanpopulations at around 2-9% but at elevated frequencies in Africans including Libyans [15][16][17]. We now report how this excimerstrategy can permit detection of an allelic variant of the human CYP3A4*1B gene sequence.…”